Erin Parsons

Erin was appointed as an independent Director for Kiora Pharmaceuticals in early 2022. She brings extensive knowledge and experience of the eyecare industry and a broad clinical understanding of major ophthalmic diseases. During her career, she participated in the commercialization of XIIDRA, OXERVATE, LUCENTIS, BEOVU, DUREZOL, and ZIRGAN, among others.

In 2010, she founded Parsons Medical Communications where she currently serves as President. This leading agency provides scientific and strategic consulting to small and large companies in the ophthalmic space. Prior to PMC, she was a founding member of Sirion Therapeutics where she led the Medical Communications department. Erin is involved with various associations in the eyecare space including Ophthalmic World Leaders, Ophthalmic Innovation Summit, and The Holland Foundation for Sight. Erin holds a BS in Biology from Wake Forest University.